Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 11/20 | 0.75 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | INSR | P06213 | 2/20 | 0.53 |
| ▸ | MET | P08581 | 2/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | TEK | Q02763 | 2/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576522 | 0.80 | PTGS2 (0.63) | PTGS2NTRK1 | |
| SCHEMBL20200 | 0.77 | PTGS2 (0.49) | IGF1RPTGS2NTRK1 | |
| SCHEMBL31592244 | 0.76 | IGF1R (0.77) | IGF1RPLK4EGFRINSRMET | |
| SCHEMBL31592498 | 0.75 | IGF1R (0.84) | IGF1RPLK4EGFRINSRMET | |
| SCHEMBL31592369 | 0.74 | IGF1R (0.67) | IGF1RPLK4EGFRINSRMET | |
| SCHEMBL31592443 | 0.74 | IGF1R (0.65) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL6311579 | 0.73 | AURKA (0.73) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL31592346 | 0.73 | IGF1R (0.66) | IGF1RPLK4EGFRINSRMET | |
| SCHEMBL31592378 | 0.73 | IGF1R (0.68) | IGF1RPLK4EGFRINSRMET | |
| SCHEMBL31592413 | 0.73 | IGF1R (0.69) | IGF1RPLK4EGFRINSRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | IGF1R 1/4885PLK4 3527/4885PTGS2 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.